Search

Displaying results 4511 - 4520 of 7602 in total
  1. Drug

    Flunarizine

    go.drugbank.com/drugs/DB04841
    ApprovedInvestigational

    Flunarizine is a selective calcium entry blocker with calmodulin binding properties and histamine H1 blocking activity. It is effective in the prophylaxis of migraine, occlusive peripheral vascular disease, vertigo of central and periphe...

    Products: NATIL N 5MG, NATIL N 10MG
  2. Drug

    Pentolinium

    go.drugbank.com/drugs/DB01090
    Approved

    Pentolinium is a nicotinic antagonist that has been used as a ganglionic blocking agent in hypertension.

  3. Drug

    IDD-1

    go.drugbank.com/drugs/DB05439
    Experimental

    Lipids promote the fusion of liposomes to cells. … As with other monoclonal antibodies, this process stimulates an immune response to a particular disease-related antigen.

  4. Drug

    SP1049C

    go.drugbank.com/drugs/DB04978
    Experimental

    Preliminary data, in its first clinically tested indication, shows that SP1049C is active in Stage IV non-resectable adenocarcinoma of the esophagus. … [A260416] It is designed to overcome drug resistance in a number of cancers. It has successfully completed Phase 1 trials. Phase 2 results are currently under final review.

  5. Drug

    Josamycin

    go.drugbank.com/drugs/DB01321
    Investigational

    A macrolide antibiotic from Streptomyces narbonensis. The drug has antimicrobial activity against a wide spectrum of pathogens.

  6. Drug

    ICG-136

    go.drugbank.com/drugs/DB17343
    Experimental

    ICG-136 is a compound chimeric antigen receptor (cCAR) T-cell therapy developed by iCell Gene Therapeutics. It was investigated for the treatment of acute myeloid leukemia.

  7. Drug

    LuLym-T

    go.drugbank.com/drugs/DB17405
    Experimental

    Developed by Lukas Biomedical, Inc., it is currently being investigated in hepatocellular carcinoma.

  8. Drug

    Mozafancogene autotemcel

    go.drugbank.com/drugs/DB17723
    Investigational

    RP-L102 is a lentiviral vector carrying the Fanconi Anemia-A (FANCA) gene currently being developed by Rocket Pharmaceuticals for the treatment of Fanconi anemia type A

  9. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    It is developed by Breakthrough Therapeutics and has completed phase I of its clinical trial.

  10. Drug

    ETC-588

    go.drugbank.com/drugs/DB05456
    Experimental

    It is believed that the removal of cholesterol by ETC-588 through this pathway may result in the reversal of atherosclerosis. … LUV are capable of transporting excess cholesterol from the vasculature to the liver for eventual elimination as part of the reverse lipid transport (RLT) pathway.